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ABSTRACT
The best way to debunk a scientific dogma is to throw irrefutable evidence at it. This is 
especially true if the dogma in question has been nurtured over many decades, as is the case 
with the apparent redundancy of antibodies (Abs) against intracellular pathogens. Although not 
fully compelling yet, that ‘hard core’ evidence is nevertheless now slowly beginning to emerge. 
This is true for several clinically relevant infections but none more so than Mycobacterium 
tuberculosis, the archetype intracellular pathogen that poses a great health challenge to the 
mankind. Here, prompted by a spate of recent high-profile reports on the effects of Abs 
in various experimental models of tuberculosis, we step back and take a critical look at the 
progress that has been made in the last 5 years and highlight some of the strengths and 
shortcomings of the presented evidence. We conclude that the tide of the opinion has begun 
to turn in favour of Abs but we also caution against overinterpreting the currently available 
limited evidence. For, until definitive evidence that can withstand even the most rigorous of 
experimental tests is produced, the dogma may yet survive. Or indeed, we may find that the 
truth is hidden somewhere in between the dogma and the unfulfilled scientific prophecy.
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INTRODUCTION
Tuberculosis (TB) overtook HIV as the biggest killer among infectious diseases caused 
by a single pathogen, killing 1.3 million people in 2017 (1). The Bacillus Calmette Guerin 
(BCG) vaccine is largely ineffective and efforts to develop a better vaccine are gathering pace 
(2). However, a major obstacle in these efforts is the lack of understanding of what makes 
protective immunity in TB and consequently, the lack of correlates of protection in vaccine 
design. Cellular immunity is known to contribute significantly to the control of Mycobacterium 
tuberculosis (MTB) infection (3) but the role of humoral immunity remains contentious. In fact, 
until a few years ago, the overwhelmingly prevailing view was that Abs have no role to play in 
immunity to TB.
MTB is considered to be a facultative intracellular pathogen residing predominantly in lung 
alveolar macrophages. It is for that reason that it was thought that Abs could not gain access 
to MTB bacilli and therefore could not play a significant role in protection. But what makes 
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an intracellular pathogen? Is any pathogen ever truly intracellular? For example, nobody ever 
questions the role of Abs against viruses, the obligatory intracellular pathogens. Viruses can 
only multiply inside a living cell and can only survive but not multiply extracellularly for a 
limited period of time. Yet, it is in this extracellular phase that they are most vulnerable to 
Abs. Indeed, most of the protective anti-viral immunity is based on neutralising or blocking 
Abs, either during the initial infection or subsequent viremia. So, what is the difference to 
other, non-viral intracellular pathogens, such as bacteria or parasites? Although they reside 
and multiply within cells, they too, just like viruses, have to leave the infected cell at some 
point and look for a new host cell. They too could be vulnerable to the interception by Abs 
and although the outcomes of those interactions are yet to be fully understood, this serves 
to illustrate that no pathogen is ever exclusively intracellular. It also serves to illustrate that 
the current dogma that Abs cannot play a protective role against the so-called intracellular 
bacterial pathogens, whether they be obligatory or facultative, is not evidence based but born 
of the lack of sufficient understanding of the pathogenesis of the infection. In this article, it 
is our intention to review the current state of knowledge about the role of Abs in TB, focusing 
in particular on the progress that has been made in the last 5 years. The reader is further 
directed to other recent reviews (4,5) listing various Abs that have been used against MTB and 
the proposed mechanisms of action.
THE HISTORIC PERSPECTIVE
Ab based immunotherapy was initially termed “serum therapy” and was first developed 
by Behring and Kitasato in the 1880s. Sera were derived from either vaccinated humans 
or animals, and the polyclonal antisera were used to treat a range of diseases. The term 
polyclonal is used as the antisera contained a mixture of different Abs which bind to a 
number of epitopes of an Ag, or different Ags altogether. Due to issues with purity and 
the polyclonal nature of the Abs, serum therapy in its infancy had variable outcomes and 
a wide range of side effects. These side effects were minimised with the subsequent use 
of monoclonal Abs (mAbs) produced by hybridoma technology and most recently, fully 
humanised Abs that can be produced at a commercially viable scale. Nowadays, mAb 
therapies are economically very significant, accounting for some of the highest selling 
biotechnology drugs (6). However, most of these mAbs are used for non-communicable 
diseases and relatively much less progress has been made with mAbs for infectious diseases. 
This can be largely attributed to the rise of sulphonamide antibiotics before the development 
of hybridoma technology and the obvious cost/effectiveness implications. However, the 
increasing threat of drug resistance today has renewed interest in the use of mAbs to treat 
drug resistant infections, for which the treatment options are arduous and limited. An 
example of such resistant infection is the multi-drug resistant TB, the incidence of which is 
increasing globally at an alarming rate.
Outside the immunotherapy context, understanding of the role of Abs in protection against 
MTB is even more important, for TB is a disease in a desperate need of a better vaccine 
than BCG if the current global epidemic is to be arrested. The BCG vaccine, which shows 
variably efficacy around the world ranging from 0%–80% (7), is thought to rely solely on 
induction of cellular immunity against mycobacteria for protection. Indeed, alongside the 
zoster vaccine (8), it is the only vaccine to do so, among hundreds of vaccines currently in 
use around the world. Both BCG and its pathogenic relative MTB induce humoral immune 
responses but they tend to be muted and unreliable as a potential diagnostic target, in 
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contrast to many other infectious diseases. This leads one to speculate that mycobacteria 
may actively manipulate the host's immune response and skew it towards bacterial growth 
restricting but ultimately ineffective cell-mediated pro-inflammatory phenotype, as a ploy to 
avert the potentially damaging action of Abs. Be that as it may, it is now clear that any future 
TB vaccine design will do well to consider the potential value of inducing a functional Ab 
response alongside the strong cell mediated immunity. That is why the currently escalating 
interest in the role of Abs in TB is critical to the conclusion of this long-standing debate in 
the scientific community and their recognition as a protective element in anti-TB immunity.
EMERGING AND RE-EMERGING THEMES
Several important contributions have been made in recent years towards better 
understanding of the role of Abs in MTB infection. While the experimental approaches and 
models of infection differed, several important themes have emerged from these studies, as 
summarised in Table 1. While some of these themes are entirely new (themes 1 and 2), others 
draw their origins from previous historical evidence but are re-emerging now with a new 
impetus for their further experimental exploration utilising novel tools, concepts and models 
of infection. Coupled with further detailed investigation of the mechanisms of protection 
involved, these themes offer a unique platform on which to build on our current knowledge 
and continue advancing this field of research.
EMERGING THEME 1
Abs Associated with Latent Infection Are More Protective Than Those from TB 
Patients
New evidence for the role of Abs in TB can be found in a recent study by Lu et al. (9) who 
investigated the differences in Abs between patients with active TB disease and those with 
latent MTB infection. The study reported that individuals with latent and active TB have 
distinct Ab responses and that Abs associated with latent infection have superior functional 
properties. Importantly, pre-incubating MTB with latency-associated Abs before infection of 
human blood derived macrophages decreased the burden of infection significantly compared 
to pre-incubating MTB with Abs from active TB infection. This could be due to shuttling 
the bacilli through pathways resulting in intracellular killing via cell surface Fc receptors, or 
intracellular Fc receptors such as TRIM21 (10) as suggested by the authors.
Another study also set out to determine the effects of human anti-TB Abs but in a mouse 
model of infection. Thus, Li et al. (11) have investigated the protective role of polyclonal 
antisera from healthcare workers exposed to MTB. The study found that Abs (predominantly 
IgG3) from healthcare workers who were latently infected or uninfected showed a protective 
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Table 1. Emerging themes for the role of Abs in TB
No. Emerging theme References
1 Abs from latently infected individuals are more protective than those from 
TB patients
(9,11,13)
2 Ab glycosylation profiles may be associated with different cellular functions (9,15)
3 Ab isotype may play a role possibly dependent on stage of infection and 
microenvironment
(13,16,18,25–27,30)
4 Abs are targeted to cell wall components of MTB but possibly also and 
other surface molecules and secreted proteins
(13,16,18,25–27,30,31,39)
effect in mice challenged with MTB by the aerosol route. In agreement with the above studies, 
the Abs from healthcare workers were more protective than those from TB patients and this 
appears to be the most consistent emerging theme from these recent studies. However, it is 
unclear whether these human Abs could display their full protective potential in mice but the 
authors rely on at least partial cross-reactivity of the human-mouse Ig-FcR system (12).
Another recent study by Zimmermann et al. (13) reported generation of several human 
recombinant IgA and IgG anti-TB Abs using cells from TB patients and their exposed 
contacts. These Abs were then tested for their MTB inhibitory activity using the human lung 
epithelial cell line A549 and the primary human lung epithelial cells. In agreement with 
above 2 studies, it appeared that Abs from household contacts (presumably latently infected) 
performed better than Abs from TB patients. The limitation of this and the Lu et al. (9) study 
is that the MTB inhibition was performed only in vitro thus potentially missing on the Ab 
effects and mechanisms that are operational only in a complex in vivo environment.
EMERGING THEME 2
Glycosylation Profile Is Associated with Divergent Functions
Lu et al. (9) analysed the differences in glycosylation profiles of Abs between active TB 
and latent TB infection (LTBI) by capillary electrophoresis. Surprisingly, the 2 sets of Abs 
clustered as distinct glycan signatures although significant within-the-group heterogeneity 
was also observed, likely representing different spectra of the infection. Interestingly, serum 
IgG from LTBI individuals contained less fucose, which is known to enhance binding to 
FcγRIII (14) and higher galactose and sialic acid content, both of which are known to be anti-
inflammatory. Similar trend was observed with both total and purified protein derivative-
specific serum IgG indicating that active MTB infection may be capable of subverting the 
hosts Ab repertoire as a whole, just as it does with many other components of immune 
response. Indeed, in another recent study (15) it was reported that infection of mice with 
MTB modified glycosylation of serum proteins and notably IgM Abs and that fucosylation 
and sialylation were most affected.
These glycosylation differences could lead to new biomarkers of disease and also diagnostic 
tests to differentiate between active and LTBI. In the context of immunotherapy, the 
differences in glycosylation between active or LTBI and their potential influence in 
intracellular killing is of considerable interest as they may aid in the development of more 
efficacious monoclonal Abs
EMERGING THEME 3
Ab Isotype Plays a Role
Zimmermann et al. (13) tested several human recombinant IgA and IgG anti-TB Abs for their 
MTB inhibitory activity using human lung epithelial cells. Interestingly, the IgA Abs specific 
for lipoarabinomannan (LAM) and heparin-binding haemagglutinin (HBHA) restricted 
infection whereas IgG Abs exacerbated it. However, the isotype dependent contrasting 
activities of IgA and IgG observed in that study are somewhat puzzling considering that 
epithelial lung cells do not express the conventional Fc-Ig receptors although they do express 
the FcRn (neonatal) receptor. Unfortunately, the authors in this study reported only a limited 
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evidence for the activity of these Abs in human macrophage cells which are known to express 
abundant Fc-γ and Fc-α receptors.
Nevertheless, the Zimmerman et al. (13) study is agreement with our own studies with murine 
(16,17) and human — (18) and unpublished—monoclonal Abs that showed IgA to be superior 
to IgG Abs of the same Ag specificity, at least when applied mucosally.
Thus, our own early studies using monoclonal IgA and IgG Abs against α-crystallin (Acr) Ag 
of MTB demonstrated superior effect of IgA, as measured by reduced bacterial counts and 
granulomas in mice (16,17). Furthermore, the IgA mAb was also shown to suppress relapse of 
infection after incomplete drug treatment (19). In both instances the IgA mAb was given to 
mice intranasally and the best treatment outcome was achieved when combining with IFN-γ, 
a proinflammatory cytokine which is thought to play an essential role in controlling MTB 
infection. We then generated a novel fully humanised IgA mAb (2E9IgA) (18) by screening a 
naïve human single chain fragment phagemid library against the MTB Acr Ag, an abundant 
Ag found on the surface and in the cytosol of MTB as well as BCG. Acr is upregulated 
in mycobacterial dormancy (20,21), and this provides the basis of the rationale behind 
development of an anti-Acr mAb. To investigate the efficacy of 2E9IgA, we used BALB/c 
transgenic mice (22,23), which express the CD89 receptor required for IgA binding to host 
cells. This was because wild type BALB/c mice do not express a homologue for CD89 (24), 
which is required for host mediated effects of IgA. CD89 transgenic mice were inoculated 
with 2E9IgA and IFN-γ (combined immunotherapy) intranasally and challenged with H37Rv 
either before or after combined immunotherapy. The level of infection was then quantified in 
lung and spleen homogenates, and we found that the combined immunotherapy significantly 
reduced colony-forming unit (CFU) in mice compared to the negative control group receiving 
saline solution (18).
Nevertheless, isotype superiority may also depend on Ag specificity since other studies have 
demonstrated that IgG Abs can also be protective (25–27). Thus, in early studies, Teitelbaum 
et al. (27) investigated 2 murine monoclonal Abs against arabinomannan (AM), 9d8 and 5c11, 
which were IgG3 and IgM, respectively (27). The study found that while both 9d8 and 5c11 
showed binding to AM by ELISA, only 9d8 showed protection against in vivo challenge with 
virulent MTB in mice. Mice given 9d8 displayed increased survival compared to those treated 
with an isotype control, although their lung CFU counts remained unchanged. Interestingly, 
mice treated with 9d8 presented significantly higher granuloma formation, which the authors 
attributed to the release of cytokines such as TNF-α due to host mediated Ab responses.
In another study, however, an anti-LAM IgG1 given to mice intravenously reduced lung 
bacterial counts and granulomatous infiltration (26), demonstrating that anti-LAM IgG Abs 
can also be protective. In agreement with this, de Vallière et al. (28) demonstrated the role 
of LAM specific IgG Abs in human volunteers. Volunteers were given 2 doses of intradermal 
BCG 6 months apart, and serum samples containing MTB-specific IgG Abs were collected 
and shown to be predominantly directed to LAM. These Abs were tested in vitro where it 
was found that they increased internalization of BCG in phagocytic cells, suggesting that 
opsonisation is a potential mechanism of action for these Abs. The study also demonstrated 
increased killing of BCG by phagocytic cells in vitro after the addition of serum LAM Abs, 
possibly by increased phagosome-lysosome fusion, and this was specific to the IgG present 
in the serum sample as serum treated with protein G (to remove IgG) did not show increased 
killing of BCG.
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Furthermore, reduction in post-chemotherapy relapse was reported in a study in which IgG 
Abs from mice immunised with detoxified MTB extract were transferred to naïve recipient 
mice (29). In addition to these studies, Abs of the IgG2a or IgG3 subtype against the HBHA 
reduced the infection in the spleens but not lungs of infected mice, suggesting that these 
particular IgG Abs could inhibit bacterial dissemination from lungs to other organs (30).
EMERGING THEME 4
Abs Target Surface and Nonsurface Ags
In a recent study, Prados-Rosales et al. (31) reported that a conjugate vaccine made of AM 
and Ag85B induced strong Ab responses to both components and when these Abs were 
transferred to naïve mice they were found to reduce MTB infection in a dose dependent 
manner. Interestingly, while the authors focus predominantly on AM-specific Abs, the 
fact that Ag8B also induced protective Abs is of utmost interest. Ag85B is not a classical 
target in anti-TB Ab studies as it is not a cell wall component but an enzyme involved in cell 
wall synthesis and then secreted into extracellular environment by the bacterium. While 
numerous studies (32–37) have shown that Ag85B is strongly immunogenic and potentially 
protective as a vaccine component, little is known about its role once secreted by the 
bacteria. If indeed Abs against this Ag are protective as evidenced in the Prados-Rosales et 
al. (15) study, this could mean that Ag85B has a secondary, virulence-associated role apart 
from being mycolyl-transferase involved in cell wall synthesis. Indeed, Ag85B can be found 
in abundance in lung cell homogenates of MTB infected mice (38) and could be involved in 
modulating bacterial environment to facilitate infection of the new host cells.
Another study also focused on AM Abs but this time induced by BCG vaccination (39). In 
that study, sera from BCG vaccinated subjects were tested for their opsonic properties and 
effect on phagocytosis and intracellular survival in human macrophages. The authors report 
enhanced phagocytosis and phago-lysosomal fusion when BCG was opsonised with Abs 
and this also resulted in restricted intracellular survival. The obvious limitation of this study 
is that BCG was used rather than MTB, and with the latter well known to be able to inhibit 
phago-lysosome fusion (40,41), it remains to be seen if these effects could be reproduced 
with MTB.
While Ag85B represents an interesting target for anti-TB Ab action, it is not the only non-
cell wall component that appears to be able to induce potentially protective Ab responses. 
While most of the studies still focus on classical cell wall components such as AM, LAM, or 
mannosylated LAM (26,27,39), there are several other Ags that are currently of interest as Ab 
targets, including Ag85B (13,31), early secreted antigenic target of 6 kDa (ESAT-6) (13), HBHA 
(16), Acr (16,18), MPB83 (25) and a number of unidentified bacterial lysate Ags (13). Further 
antigenic targets for Abs have been identified in a recent study by Coppola et al. (42) who 
analysed IgG levels and specificities in sera of patients and controls in an endemic TB setting. 
They observed that Ab levels to particular Ags associated with bacterial burden and control 
vs progression of disease. Some of these Ags may appear on the cell surface transiently 
or indeed may be secreted to the cell culture, such as Ag85B and ESAT-6. Either way, they 
offer additional opportunities for Abs to exert their protective functions and so, the list of 
the potential new targets is constantly expanding. It is therefore quite plausible that some 
of these Abs could work synergistically, by targeting different bacterial components and 
virulence mechanisms employed at different stages of the infection.
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POSSIBLE MECHANISMS OF ABS ACTION IN TB
The protective mechanisms of Abs in TB are likely to be diverse and dependent on their Ag 
specificity, isotype and site of secretion or route of delivery if applied as immunotherapy. 
It is indisputable that the tubercle bacilli are released from necrotic lesions in significant 
numbers (43) and that means that Abs could gain access to these extracellular bacilli 
and influence both their FcR-mediated uptake by uninfected macrophages (18,27,39) 
or dissemination throughout the lungs and other organs (30). Similar, but Fc-receptor 
independent action has been proposed also for mAb blocking of the action of LAM 
(26) by diverting the MTB away from the mannose receptors towards more bactericidal 
receptors. This may lead to enhanced phagocytosis, phago-lysosomal fusion and decreased 
intracellular survival, as proposed in some studies (18,28,39). In addition, some IgG Abs 
were shown to enhance the mycobacterium specific IFN-γ production by CD4+ and CD8+ 
T cells (28) offering yet another potential mechanism of Ab mediated anti-TB immunity. 
Also, Abs may contribute to the maturation of dendritic cells and enhancement of MHC 
class I restricted presentation of antigenic peptides to T cells (44). Some of these potential 
mechanisms of Ab action against TB are schematically illustrated in Fig.1 but this is certainly 
not an exhaustive list and other yet unidentified mechanisms may come to light as the 
research in this field gathers pace.
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Figure 1. Schematic representation of some of the proposed mechanisms of Ab action against MTB infection.
THE EVIDENCE AGAINST
While all providing a supporting evidence that Abs can be protective in TB, none of the above 
studies has yet provided definitive, hard-core evidence that we called upon at the beginning 
of this review. It is therefore important to also consider the evidence that discounts the 
role of Abs in TB so that a balanced view can emerge. Thus, the strongest argument that 
Abs do not contribute to protection against TB comes from numerous preclinical vaccine 
studies showing strong Ab responses but minimal or no protection; an example of one such 
study is described in (45). In other words, Ab responses do not appear to be correlated with 
protection. However, as a counter argument to that, one can draw a parallel to IFN-γ, an 
important pro-inflammatory macrophage-activating cytokine in immunity to TB. Although 
the essential role of IFN-γ in TB is indisputable as shown by many experimental and clinical 
studies (46), it appears to be no more than a prerequisite of protection rather than a correlate 
of it. Similarly, Abs could have a significant role in protection but alone are not sufficient in 
the absence of other yet unidentified correlates of protection. This is quite plausible given 
that MTB infection is incredibly complex and stage driven so that different elements of 
immunity are required at different stages of infection to achieve control.
Another argument against the role of Abs comes from the B cell knockout mouse studies. 
One such recent study reported that B cells (and therefore Abs) are not required for 
protection against MTB imparted by a viral subunit mucosal vaccine (47). In contrast, T cells 
were shown to be essential for protection in that study. Again, a counter argument to that 
comes from previous studies showing contrasting results, where B cell deficient mice were 
shown to be more susceptible to MTB infection (48), while lung granulomas of non-human 
primates infected with MTB showed the presence of activated B cells (49). Furthermore, and 
as a yet another layer of complexity in regards to B cells, they were also proposed to have a 
regulatory role in TB (50).
CONCLUDING REMARKS
Further essential research is required in both animal experimental models and humans 
that could shed further light on the role of Abs in TB. Concerns may be raised about the 
impact of vaccine induced Abs in experimental models of infection as well as the efficacy 
of passive Ab treatment. The experimental results from the recent studies described in this 
review showed merely a reduction in counts of viable organisms, whether in mice or infected 
cell lines. This is in stark contrast to sterilising potency which can be imparted by drugs. 
This could be due to inadequate experimental models, high infection doses compared to 
humans and absence of other elements of immunity. Since no vaccine candidate against TB 
has yet imparted sterilising immunity in any of the experimental models, it is unlikely that 
Abs could achieve that alone—that would be setting the bar too high. However, the present 
encouraging evidence suggests they could yet play a significant role in both vaccine design 
and immunotherapy of TB. That paradigm shift has already occurred and it is only a matter of 
time before we can begin to harness the wide range of anti-mycobacterial activities. To that 
effect, the research over the past 5 years has given us some clear pointers and although the 
definitive evidence is yet to come, there are already several emerging themes. These themes 
represent the pieces of a jigsaw that is becoming more and more complete with each new 
piece of evidence in support of the protective role of Abs in TB.
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